Qilu Pharmaceutical Co., Ltd.

This study tests several combinations of the experimental drug QLS32015 with other medicines in 160 people whose multiple myeloma has come back or stopped responding to prior therapy. The goal is to see which combination works best to shrink tumors and achieve deep remission. Par…

This Phase 3 trial is testing whether a new drug called QL2106 works as well as the approved medication Tremfya for people with moderate to severe plaque psoriasis. About 318 participants will receive either QL2106 or Tremfya injections over several months. The main goal is to se…

This study tests several new drug combinations for men with advanced prostate cancer that has spread. The experimental drugs include QLC5508 (a targeted therapy that delivers a toxin to cancer cells) and QLH12016 (a drug that breaks down the male hormone receptor). These are comb…

This study tests a new drug called QLS32015 against two standard treatment combinations (pomalidomide with dexamethasone or selinexor with dexamethasone) in 228 people with multiple myeloma that has relapsed or is refractory. The main goal is to see if QLS32015 can delay cancer p…

This study tests a new drug called QLS1304 combined with standard hormone therapy in people with advanced ER+/HER2- breast cancer whose disease has worsened after at least one prior hormone treatment. The trial has two phases: first finding the best dose, then checking how well i…

This early-stage trial is testing a new drug, QLS5212, in 100 people with advanced solid tumors that cannot be removed by surgery or have spread. The drug is an antibody-drug conjugate designed to deliver a cancer-killing agent directly to tumor cells. The main goals are to find …

This study tests a new drug called QLC5508 against standard chemotherapy in people with advanced esophageal cancer that has worsened after prior treatment. About 466 adults will be randomly assigned to receive either QLC5508 or a chemotherapy chosen by their doctor. The main goal…

This study tests two experimental drugs, QLP2117 and QL2107, given together to people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the combination can shrink tumors. About 149 participants will be enrolled i…

This phase 3 trial tests a new antibiotic combination (meropenem and pralurbactam) against an existing one (ceftazidime and avibactam) for treating hospital-acquired and ventilator-associated bacterial pneumonia. About 420 adults will participate, and the main goal is to see if t…

This early-stage trial tests an experimental drug called QLS-1304 in 180 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and get a first look at whether it can shrink tumors. Par…

This early-stage study tests an experimental drug called QLS2309 in about 186 adults with CD70-positive blood cancers that have returned or not responded to standard therapy. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Parti…

This study tests a new drug called QL1706 given before surgery for people with a specific type of colon cancer (MSI-H/dMMR) that has not spread far. About 363 participants will receive either QL1706 or standard care. The goal is to see if QL1706 can eliminate more tumor tissue be…

This study tests a new drug called QLC5508, given with other anti-cancer medicines, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find the safest dose and see if the combination can shrink tumors. About 444 adults will t…

This Phase 3 trial is testing whether adding an experimental drug called QLS31905 to standard chemotherapy helps people with advanced pancreatic cancer live longer. The study includes 602 adults whose tumors have a specific marker (CLDN18.2). Participants are randomly assigned to…

This Phase 3 trial is testing a new drug called ESG401 against standard chemotherapy for people with advanced triple-negative breast cancer that has spread or come back. The study will enroll about 504 participants to see if ESG401 can delay cancer growth and improve survival. It…

This study tests whether a daily pill called relugolix can safely reduce heavy menstrual bleeding in women with uterine fibroids. About 120 premenopausal women will receive either relugolix or a placebo for several weeks. The main goal is to see if the drug lowers blood loss to n…

This study tests a drug called QL0911 for people whose platelet levels drop too low due to cancer treatment. Low platelets can delay chemotherapy and cause bleeding risks. The trial will compare QL0911 to a placebo in 235 adults aged 18-75 to see if it safely raises platelet coun…

This early-stage trial in 16 healthy adults in China measures how much of the intravenous antibiotic Meropenem-Pralubactam gets into lung fluids and cells. Researchers aim to find the drug's concentration in plasma, epithelial lining fluid, and alveolar macrophages after four dos…